Apixaban (English Wikipedia)

"Apixaban (Eliquis) Use During Pregnancy". Drugs.com. 21 June 2019. Retrieved 13 August 2020.
"Apixaban Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Retrieved 27 March 2019.

drugstorenews.com (Global: low place; English: low place)

Levy S (1 August 2022). "Apotex offers generic Eliquis in Canada". Drugstore News. Retrieved 2 September 2022.

elsevier.com (Global: 610^th place; English: 704^th place)

linkinghub.elsevier.com

Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. (January 2021). "Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis". European Journal of Vascular and Endovascular Surgery. 61 (1): 9–82. doi:10.1016/j.ejvs.2020.09.023. hdl:10362/147427. PMID 33334670.
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. (November 2012). "Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial". Lancet. 380 (9855). London, England: 1749–1758. doi:10.1016/S0140-6736(12)60986-6. PMID 23036896.

europa.eu (Global: 68^th place; English: 117^th place)

ema.europa.eu

"Eliquis EPAR". European Medicines Agency. 17 September 2018. Retrieved 22 April 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

fda.gov (Global: 447^th place; English: 338^th place)

fda.gov

"FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
"Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)". U.S. Food and Drug Administration (FDA). 31 December 2018. Archived from the original on 29 May 2020. Retrieved 22 April 2020.
"2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

accessdata.fda.gov

"Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Archived from the original on 28 June 2013. Retrieved 23 December 2019.
"FDA-Approved Drugs: Eliquis (apixaban)". U.S. Food and Drug Administration (FDA). Archived from the original on 17 February 2017. Retrieved 23 December 2019.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. (21 February 2013). "Apixaban for Extended Treatment of Venous Thromboembolism". The New England Journal of Medicine. 368 (8): 699–708. doi:10.1056/NEJMoa1207541. hdl:2445/178572. ISSN 0028-4793. PMID 23216615.
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. (January 2021). "Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis". European Journal of Vascular and Endovascular Surgery. 61 (1): 9–82. doi:10.1016/j.ejvs.2020.09.023. hdl:10362/147427. PMID 33334670.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. (September 2009). "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 361 (12): 1139–1151. doi:10.1056/NEJMoa0905561. hdl:11343/221723. PMID 19717844.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. (25 August 2011). "Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome". The New England Journal of Medicine. 365 (8): 699–708. doi:10.1056/NEJMoa1105819. hdl:2066/95648. ISSN 0028-4793. PMID 21780946.

harvard.edu (Global: 18^th place; English: 17^th place)

ui.adsabs.harvard.edu

Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E (2019). "Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study". PLOS ONE. 14 (8) e0221500. Bibcode:2019PLoSO..1421500K. doi:10.1371/journal.pone.0221500. PMC 6709911. PMID 31449560.

hhs.gov (Global: 5,973^rd place; English: 3,693^rd place)

aspe.hhs.gov

"Medicare Drug Price Negotiation Program: Medicare Prices Negotiated for 2026 Compared to List and U.S. Market Prices" (PDF). Office of the Assistant Secretary for Planning and Evaluation, U.S. Department of Health and Human Services. 15 August 2024.

jdsupra.com (Global: low place; English: low place)

"Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc". JD Supra. Retrieved 30 November 2021.

medicaldialogues.in (Global: low place; English: low place)

business.medicaldialogues.in

"FIRST: Mylan, Micro Labs get USFDA nod for generic version of blood thinner Eliquis". Business Medical Dialogues. New Delhi, India: Minerva Medical Treatment. 24 December 2019. Retrieved 24 December 2019.

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

"Eliquis 5 mg film-coated tablets - Summary of Product Characteristics (SmPC)". (emc). 3 May 2022. Retrieved 8 October 2022.

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

Neale T (14 March 2014). "FDA OKs Apixaban for DVT Prevention". MedPage Today. Retrieved 17 September 2015.

natlawreview.com (Global: 9,177^th place; English: 5,024^th place)

"Federal Circuit Crystallizes BMS' Apixaban District Court Win". The National Law Review. Retrieved 30 November 2021.

nbcnews.com (Global: 137^th place; English: 101^st place)

Lovelace Jr B (15 August 2024). "Medicare announces lower prices on 10 common, high-cost drugs". NBC News. Retrieved 21 August 2024.

nejm.org (Global: 2,374^th place; English: 6,027^th place)

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. (21 February 2013). "Apixaban for Extended Treatment of Venous Thromboembolism". The New England Journal of Medicine. 368 (8): 699–708. doi:10.1056/NEJMoa1207541. hdl:2445/178572. ISSN 0028-4793. PMID 23216615.
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, et al. (10 April 2025). "Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism". The New England Journal of Medicine. 392 (14): 1363–1373. doi:10.1056/NEJMoa2416112. ISSN 0028-4793. PMID 40162636.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. (25 August 2011). "Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome". The New England Journal of Medicine. 365 (8): 699–708. doi:10.1056/NEJMoa1105819. hdl:2066/95648. ISSN 0028-4793. PMID 21780946.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (3 March 2011). "Apixaban in Patients with Atrial Fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. ISSN 0028-4793. PMID 21309657.

nice.org.uk (Global: 3,258^th place; English: 2,666^th place)

"Atrial fibrillation: diagnosis and management" (PDF). National Institute for Health and Care Excellence. January 2021.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978.
Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E (2019). "Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study". PLOS ONE. 14 (8) e0221500. Bibcode:2019PLoSO..1421500K. doi:10.1371/journal.pone.0221500. PMC 6709911. PMID 31449560.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (March 2011). "Apixaban in patients with atrial fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. PMID 21309657.
Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P (March 2010). "Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial". Lancet. 375 (9717): 807–815. doi:10.1016/S0140-6736(09)62125-5. PMID 20206776.
Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM (December 2010). "Apixaban versus enoxaparin for thromboprophylaxis after hip replacement". The New England Journal of Medicine. 363 (26): 2487–2498. doi:10.1056/NEJMoa1006885. PMID 21175312.
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. (21 February 2013). "Apixaban for Extended Treatment of Venous Thromboembolism". The New England Journal of Medicine. 368 (8): 699–708. doi:10.1056/NEJMoa1207541. hdl:2445/178572. ISSN 0028-4793. PMID 23216615.
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, et al. (10 April 2025). "Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism". The New England Journal of Medicine. 392 (14): 1363–1373. doi:10.1056/NEJMoa2416112. ISSN 0028-4793. PMID 40162636.
Couturaud F, Schmidt J, Sanchez O, Ballerie A, Sevestre MA, Meneveau N, et al. (March 2025). "Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial". Lancet. 405 (10480). London, England: 725–735. doi:10.1016/S0140-6736(24)02842-3. PMID 40023651.
Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. (March 2019). "New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism". The Medical Journal of Australia. 210 (5): 227–235. doi:10.5694/mja2.50004. ISSN 0025-729X. PMID 30739331.
Stevens SM, Woller SC, Baumann Kreuziger L, Doerschug K, Geersing GJ, Klok FA, et al. (August 2024). "Antithrombotic Therapy for VTE Disease". Chest. 166 (2): 388–404. doi:10.1016/j.chest.2024.03.003. PMID 38458430.
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. (January 2021). "Editor's Choice – European Society for Vascular Surgery (ESVS) 2021 Clinical Practice Guidelines on the Management of Venous Thrombosis". European Journal of Vascular and Endovascular Surgery. 61 (1): 9–82. doi:10.1016/j.ejvs.2020.09.023. hdl:10362/147427. PMID 33334670.
Joundi RA, Cipriano LE, Sposato LA, Saposnik G, et al. (on behalf of the Stroke Outcomes Research Working Group) (May 2016). "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1: Systematic Review and Meta-Analysis". Stroke. 47 (5): 1364–1367. doi:10.1161/STROKEAHA.115.012609. ISSN 0039-2499. PMID 27026630.
Lopes RD, Al-Khatib SM, Wallentin L, Yang H, Ansell J, Bahit MC, et al. (November 2012). "Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial". Lancet. 380 (9855). London, England: 1749–1758. doi:10.1016/S0140-6736(12)60986-6. PMID 23036896.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. (September 2009). "Dabigatran versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 361 (12): 1139–1151. doi:10.1056/NEJMoa0905561. hdl:11343/221723. PMID 19717844.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. (September 2011). "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation". The New England Journal of Medicine. 365 (10): 883–891. doi:10.1056/NEJMoa1009638. PMC 3860773. PMID 21830957.
Hohnloser SH, Hijazi Z, Thomas L, Alexander JH, Amerena J, Hanna M, et al. (November 2012). "Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial". European Heart Journal. 33 (22): 2821–2830. doi:10.1093/eurheartj/ehs274. PMID 22933567.
Fernandez S, Lenoir C, Samer C, Rollason V (October 2020). "Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports". Pharmacology Research & Perspectives. 8 (5) e00647. doi:10.1002/prp2.647. ISSN 2052-1707. PMC 7507549. PMID 32881416.
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. (15 June 2016). "Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial". BMJ. 353 i2868. Clinical Research Ed. doi:10.1136/bmj.i2868. ISSN 1756-1833. PMC 4908974. PMID 27306620.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. (25 August 2011). "Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome". The New England Journal of Medicine. 365 (8): 699–708. doi:10.1056/NEJMoa1105819. hdl:2066/95648. ISSN 0028-4793. PMID 21780946.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (3 March 2011). "Apixaban in Patients with Atrial Fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. ISSN 0028-4793. PMID 21309657.
Chang KH, Chen CM, Wang CL, Tu HT, Huang YT, Wu HC, et al. (4 February 2022). "Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants". Frontiers in Aging Neuroscience. 14 791285. doi:10.3389/fnagi.2022.791285. ISSN 1663-4365. PMC 8855103. PMID 35185526.
Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C (22 March 2024). "Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding". JAMA Network Open. 7 (3): e243208. doi:10.1001/jamanetworkopen.2024.3208. ISSN 2574-3805. PMC 10960200. PMID 38517440.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.
Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.

ncbi.nlm.nih.gov

Kjerpeseth LJ, Selmer R, Ariansen I, Karlstad Ø, Ellekjær H, Skovlund E (2019). "Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study". PLOS ONE. 14 (8) e0221500. Bibcode:2019PLoSO..1421500K. doi:10.1371/journal.pone.0221500. PMC 6709911. PMID 31449560.
Lowenstern A, Al-Khatib SM, Sharan L, Chatterjee R, Allen LaPointe NM, Shah B, et al. (December 2018). "Interventions for Preventing Thromboembolic Events in Patients With Atrial Fibrillation: A Systematic Review". Annals of Internal Medicine. 169 (11): 774–787. doi:10.7326/M18-1523. PMC 6825839. PMID 30383133.
Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. (September 2011). "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation". The New England Journal of Medicine. 365 (10): 883–891. doi:10.1056/NEJMoa1009638. PMC 3860773. PMID 21830957.
Fernandez S, Lenoir C, Samer C, Rollason V (October 2020). "Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports". Pharmacology Research & Perspectives. 8 (5) e00647. doi:10.1002/prp2.647. ISSN 2052-1707. PMC 7507549. PMID 32881416.
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. (15 June 2016). "Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial". BMJ. 353 i2868. Clinical Research Ed. doi:10.1136/bmj.i2868. ISSN 1756-1833. PMC 4908974. PMID 27306620.
Chang KH, Chen CM, Wang CL, Tu HT, Huang YT, Wu HC, et al. (4 February 2022). "Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants". Frontiers in Aging Neuroscience. 14 791285. doi:10.3389/fnagi.2022.791285. ISSN 1663-4365. PMC 8855103. PMID 35185526.
Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C (22 March 2024). "Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding". JAMA Network Open. 7 (3): e243208. doi:10.1001/jamanetworkopen.2024.3208. ISSN 2574-3805. PMC 10960200. PMID 38517440.
Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. (February 2013). "Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects". British Journal of Clinical Pharmacology. 75 (2): 476–487. doi:10.1111/j.1365-2125.2012.04369.x. PMC 3558798. PMID 22759198.
Cada DJ, Levien TL, Baker DE (June 2013). "Apixaban". Hospital Pharmacy. 48 (6): 494–509. doi:10.1310/hpj4806-494. PMC 3839491. PMID 24421512.

dailymed.nlm.nih.gov

"Eliquis- apixaban tablet, film coated Eliquis 30-day starter pack- apixaban kit". DailyMed. 26 November 2019. Retrieved 22 April 2020.
"Andexxa- andexanet alfa injection, powder, lyophilized, for solution". DailyMed. 8 January 2019. Retrieved 23 December 2019.

pubchem.ncbi.nlm.nih.gov

"Apixaban". PubChem, US National Library of Medicine. 27 August 2022. Retrieved 2 September 2022.

pfizer.com (Global: low place; English: low place)

"Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds" (Press release). Pfizer. Archived from the original on 10 September 2015. Retrieved 25 December 2021.
"U.S. FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE), and for the Reduction in the Risk of Recurrent DVT and PE Following Initial Therapy" (Press release). Pfizer. 21 August 2014. Retrieved 26 February 2016.
"Pfizer's year in review". Pfizer 2023 Annual Report. 31 December 2023. Retrieved 30 December 2024.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. (September 2011). "Apixaban versus warfarin in patients with atrial fibrillation". The New England Journal of Medicine. 365 (11): 981–992. doi:10.1056/NEJMoa1107039. PMID 21870978. S2CID 43262809.

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

"Apibax apixaban 2.5 mg tablet blister pack (428660)". Therapeutic Goods Administration (TGA). 4 December 2024. Retrieved 20 January 2025.
"Apibax (Nova Pharmaceuticals Australasia Pty Ltd)". Therapeutic Goods Administration (TGA). 14 January 2025. Retrieved 20 January 2025.

web.archive.org (Global: 1^st place; English: 1^st place)

"FDA approves first generics of Eliquis". U.S. Food and Drug Administration (FDA). 23 December 2019. Archived from the original on 23 December 2019. Retrieved 23 December 2019. This article incorporates text from this source, which is in the public domain.
"Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds" (Press release). Pfizer. Archived from the original on 10 September 2015. Retrieved 25 December 2021.
"Drug Approval Package: Eliquis (apixaban) NDA #202155". U.S. Food and Drug Administration (FDA). 13 February 2013. Archived from the original on 28 June 2013. Retrieved 23 December 2019.
"Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
"Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo)". U.S. Food and Drug Administration (FDA). 31 December 2018. Archived from the original on 29 May 2020. Retrieved 22 April 2020.
"FDA-Approved Drugs: Eliquis (apixaban)". U.S. Food and Drug Administration (FDA). Archived from the original on 17 February 2017. Retrieved 23 December 2019.
"2019 First Generic Drugs Approvals". U.S. Food and Drug Administration (FDA). 5 August 2020. Archived from the original on 30 June 2023. Retrieved 30 June 2023.

wiley.com (Global: 222^nd place; English: 297^th place)

onlinelibrary.wiley.com

Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. (March 2019). "New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism". The Medical Journal of Australia. 210 (5): 227–235. doi:10.5694/mja2.50004. ISSN 0025-729X. PMID 30739331.

worldcat.org (Global: 5^th place; English: 5^th place)

search.worldcat.org

Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. (21 February 2013). "Apixaban for Extended Treatment of Venous Thromboembolism". The New England Journal of Medicine. 368 (8): 699–708. doi:10.1056/NEJMoa1207541. hdl:2445/178572. ISSN 0028-4793. PMID 23216615.
Mahé I, Carrier M, Mayeur D, Chidiac J, Vicaut E, Falvo N, et al. (10 April 2025). "Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism". The New England Journal of Medicine. 392 (14): 1363–1373. doi:10.1056/NEJMoa2416112. ISSN 0028-4793. PMID 40162636.
Tran HA, Gibbs H, Merriman E, Curnow JL, Young L, Bennett A, et al. (March 2019). "New guidelines from the Thrombosis and Haemostasis Society of Australia and New Zealand for the diagnosis and management of venous thromboembolism". The Medical Journal of Australia. 210 (5): 227–235. doi:10.5694/mja2.50004. ISSN 0025-729X. PMID 30739331.
Joundi RA, Cipriano LE, Sposato LA, Saposnik G, et al. (on behalf of the Stroke Outcomes Research Working Group) (May 2016). "Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA 2 DS 2 -VASc Score of 1: Systematic Review and Meta-Analysis". Stroke. 47 (5): 1364–1367. doi:10.1161/STROKEAHA.115.012609. ISSN 0039-2499. PMID 27026630.
Fernandez S, Lenoir C, Samer C, Rollason V (October 2020). "Drug interactions with apixaban: A systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports". Pharmacology Research & Perspectives. 8 (5) e00647. doi:10.1002/prp2.647. ISSN 2052-1707. PMC 7507549. PMID 32881416.
Jaspers Focks J, Brouwer MA, Wojdyla DM, Thomas L, Lopes RD, Washam JB, et al. (15 June 2016). "Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial". BMJ. 353 i2868. Clinical Research Ed. doi:10.1136/bmj.i2868. ISSN 1756-1833. PMC 4908974. PMID 27306620.
Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, et al. (25 August 2011). "Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome". The New England Journal of Medicine. 365 (8): 699–708. doi:10.1056/NEJMoa1105819. hdl:2066/95648. ISSN 0028-4793. PMID 21780946.
Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. (3 March 2011). "Apixaban in Patients with Atrial Fibrillation". The New England Journal of Medicine. 364 (9): 806–817. doi:10.1056/NEJMoa1007432. ISSN 0028-4793. PMID 21309657.
Chang KH, Chen CM, Wang CL, Tu HT, Huang YT, Wu HC, et al. (4 February 2022). "Major Bleeding Risk in Patients With Non-valvular Atrial Fibrillation Concurrently Taking Direct Oral Anticoagulants and Antidepressants". Frontiers in Aging Neuroscience. 14 791285. doi:10.3389/fnagi.2022.791285. ISSN 1663-4365. PMC 8855103. PMID 35185526.
Rahman AA, Platt RW, Beradid S, Boivin JF, Rej S, Renoux C (22 March 2024). "Concomitant Use of Selective Serotonin Reuptake Inhibitors With Oral Anticoagulants and Risk of Major Bleeding". JAMA Network Open. 7 (3): e243208. doi:10.1001/jamanetworkopen.2024.3208. ISSN 2574-3805. PMC 10960200. PMID 38517440.

Apixaban (English Wikipedia)

ahajournals.org (Global: 3,608th place; English: 6,526th place)

apotex.com (Global: low place; English: low place)

biopharmadive.com (Global: low place; English: low place)

biospace.com (Global: low place; English: 7,595th place)

books.google.com (Global: 3rd place; English: 3rd place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

health-products.canada.ca

clincalc.com (Global: 3,912th place; English: 2,496th place)

cms.gov (Global: low place; English: low place)

doi.org (Global: 2nd place; English: 2nd place)

drugs.com (Global: 399th place; English: 333rd place)

drugstorenews.com (Global: low place; English: low place)

elsevier.com (Global: 610th place; English: 704th place)

linkinghub.elsevier.com

europa.eu (Global: 68th place; English: 117th place)

ema.europa.eu

fda.gov (Global: 447th place; English: 338th place)

fda.gov

accessdata.fda.gov

handle.net (Global: 102nd place; English: 76th place)

hdl.handle.net

harvard.edu (Global: 18th place; English: 17th place)

ui.adsabs.harvard.edu

hhs.gov (Global: 5,973rd place; English: 3,693rd place)

aspe.hhs.gov

jdsupra.com (Global: low place; English: low place)

medicaldialogues.in (Global: low place; English: low place)

business.medicaldialogues.in

medicines.org.uk (Global: 3,823rd place; English: 2,387th place)

medpagetoday.com (Global: 9,274th place; English: 5,856th place)

natlawreview.com (Global: 9,177th place; English: 5,024th place)

nbcnews.com (Global: 137th place; English: 101st place)

nejm.org (Global: 2,374th place; English: 6,027th place)

nice.org.uk (Global: 3,258th place; English: 2,666th place)

nih.gov (Global: 4th place; English: 4th place)

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

dailymed.nlm.nih.gov

pubchem.ncbi.nlm.nih.gov

pfizer.com (Global: low place; English: low place)

semanticscholar.org (Global: 11th place; English: 8th place)

api.semanticscholar.org

tga.gov.au (Global: 3,984th place; English: 2,622nd place)

web.archive.org (Global: 1st place; English: 1st place)

wiley.com (Global: 222nd place; English: 297th place)

onlinelibrary.wiley.com

worldcat.org (Global: 5th place; English: 5th place)

search.worldcat.org

ahajournals.org (Global: 3,608^th place; English: 6,526^th place)

biospace.com (Global: low place; English: 7,595^th place)

books.google.com (Global: 3^rd place; English: 3^rd place)

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

clincalc.com (Global: 3,912^th place; English: 2,496^th place)

doi.org (Global: 2^nd place; English: 2^nd place)

drugs.com (Global: 399^th place; English: 333^rd place)

elsevier.com (Global: 610^th place; English: 704^th place)

europa.eu (Global: 68^th place; English: 117^th place)

fda.gov (Global: 447^th place; English: 338^th place)

handle.net (Global: 102^nd place; English: 76^th place)

harvard.edu (Global: 18^th place; English: 17^th place)

hhs.gov (Global: 5,973^rd place; English: 3,693^rd place)

medicines.org.uk (Global: 3,823^rd place; English: 2,387^th place)

medpagetoday.com (Global: 9,274^th place; English: 5,856^th place)

natlawreview.com (Global: 9,177^th place; English: 5,024^th place)

nbcnews.com (Global: 137^th place; English: 101^st place)

nejm.org (Global: 2,374^th place; English: 6,027^th place)

nice.org.uk (Global: 3,258^th place; English: 2,666^th place)

nih.gov (Global: 4^th place; English: 4^th place)

semanticscholar.org (Global: 11^th place; English: 8^th place)

tga.gov.au (Global: 3,984^th place; English: 2,622^nd place)

web.archive.org (Global: 1^st place; English: 1^st place)

wiley.com (Global: 222^nd place; English: 297^th place)

worldcat.org (Global: 5^th place; English: 5^th place)